Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anti-TNF Drug

PreclinicalSmall molecule

HHospices Civils de Lyon

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Crohn's Disease

NCT03681652

Clinical

Trials by Indication[1]

Crohn's Disease2 trials

Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease

Withdrawn·HHospices Civils de Lyon·N/A·NCT03712826

Post-Operative Crohn's Disease Outcome in Children

Recruiting·SSchneider Children's Medical Center, Israel··NCT03681652·100 enrolled

Complication1 trial

The Influence of Biologcal Treatment on the Short-Term Complications of Surgery in Patients With Inflematory Bowel Disease.

Completed·HHaEmek Medical Center, Israel··NCT03747068·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anti-TNF Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-TNF Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-TNF Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Related News